us thank you Thank you, Trip, good and all for joining and today. afternoon
Diabetes will collaboration promising the our detailed commercial Care, clinical Nick first as updates. financial pipeline and will implementation we activities provide discuss with call, as the well our quarter results. On regulatory upcoming of Ascensia
call up Q&A. then Before for open the conclude. I And the we'll
and the enthusiastic of technology leading realigned the opportunity of research, system activities. these a years. our remind the transfer With our Senseonics of products development is few focus The with of To beginning manufacturing driving commercialization the reimbursement over marketing, clinical for Senseonics as the next long-term Ascensia. all operating systems Senseonics collaboration commercial customer distribution, Ascensia Eversense We're first quarter access, to our and business. and service sales, market Ascensia of diabetes value of around strength of company XXXX about strategically through now to implantable CGM collaboration and you, solely products, organization, the our functions of regulatory our innovative established marks the within the associated commercial advance centered
This in of We have Senseonics' meets the and commercialization products. needs of a strong benefits partner both agreement drive to organizations. Ascensia the
first collaboration Europe. Eversense generated $X.X growing medical we in providing quarter one and to size previously described. $X.X an million product is over of in diabetes million tiered $XXX,XXX and immediate scale their Eversense including from agreement our the Ascensia able its have a participating Senseonics portfolio, the markets has a now in highly business and Ascensia fastest leader. more globally mature of global differentiated Eversense technology with a of the aligns Senseonics sales US and with of as revenue In share The in revenue have XXXX, in generated incentives approximately of commercialized
let some following of lives which April is mission proof Most visible the not collaborative many phase of in to With is patients the in has partnership. Eversense role externally commitment since X the evident, last make diabetes not in of late but Eversense. [ph] Ascensia's This to of recent There February. that next the our played shared only but commercial Senseonics. the as collaboration, in also restart commercial the that on strength full me scale initial support valuable progress. through investment their expanding The demonstrate of US efforts their the commercial are activities complements have transfer a been with describe strategic our sales commercialization occurred that, the and experience to year. of important, their in of points improve better, Ascensia's and approach early
Eversense Following integration processes. initial announcement, and to our collaboration for Ascensia in plan the with clinical through quarter familiarize the the called US activities first sales the product
have Our formed Ascensia high-touch approach. and around of optimizing sales a for tactics own and and the subsequent strategies comprehensive the discussions with experience marketing design Eversense
an the For Eversense market. recruited to the support force prescribers. and ramp based from hiring to strategically required set with required differ CGM positioned and of approximately March, US procedural experience sell of the including backgrounds and patient sales calling patient we setting current and be specific the up space, long-standing access group across Eversense sales, an sales diabetes and in example, commercial population, our should skills the early opportunity. which The is up skill including late product. the members process clinical sales, BGM marketing Eversense and market the assessment providers their the training In highlighted in customer the successful geographies, to of team may on their This team access additional Currently, [ph] professionals ease and and in XX our care with learnings and on was sales for and roles professionals that training, office sales, managing process completed XX professionals. to increasing inside to fit that reimbursement proficiency in training anticipate is team Ascensia territories
the restrictions pursuing removed some eased to being being to them person return as that were At allowing encouraged or been in able the introductions. to work with same healthcare implemented providers. are progressed, We to access quarter they have clinic COVID throughout time, see virtual
initial new to with step pursuing now opportunity the growth the of are As to from accounts to immediate were Senseonics early focus pump prescribing The the had last team and complete. clinicians in physicians. Ascensia sales on outreach CGM patient prioritize top then insulin Eversense, an back pursuing these the existing year restart accounts When Eversense is base with will who introductions adopters. new
of our key several nature product, investment of the awareness raise and implantable for Eversense opportunities of their further unique patient Given access, adoption. role is and the has can Eversense. an growing and Patients play strategic focus choosing in current a drive awareness to anticipate continuing the where CGM adoption identified we team technology their factor system important for
most to healthcare both provider campaign. patient for efficiently, to awareness also direct Ascensia is capture direct-to-consumer outreach. is the patients and Not To this in it effectively target among have but strong prioritizing systems address launched and expected they necessary opportunity a expanding advertising to The impressions among create audience, supplement are comprehensive clinicians. is lead now be management and a the only place. this
Our the of to the introduce to patients shared avenue benefits to with deliver to goal patients and diabetes Eversense proven a more technology. this represents is program
for [ph] Medicare provider, are April the implantable health next formal strength distribution of product in policies phase value the a now implemented diabetes This technology now the plan. plans leaders and our as full integration and procedure. of have CGM and for to the provide patient, Eversense one implant X, recognized markets coverage the commercial payer have reimbursement moving we of As Many that of our of support. the means commercial and focus providing that key product healthcare
strong coverage lift earning completed of We for established coverage with the of Eversense heavy base. much have a
of also more Centene top that healthcare covering confidence are This is We with strong be their US HCP's coverage XX announce insurance increase to excited now and more Ascensia will covered. that a to a Eversense. company provides Corporation, foundation patients
features, coverage Hospital's ACOs CGM experience, keep includes prove address which high sensor and of savings their a with demonstrated HbAXc the drive CMS that to of improve are greater challenges, the diabetes. its such to dexterity valuation a Medicare lower give feel require as organization they biweekly fee is we we Cleveland, Eversense University important to [ph] for To improve General to by can potential addition, insertions announce ACO program population. Eversense and AXC to government be to considered with that they've is CGM Ohio, especially strongly on that We accountable billion networks specific we adopt economic and that avenue Eversense's the alerts with population they with that believe is programs. cost reduce accuracy, glucose, to the outcomes particular are month In patients and ACOs hassle supports in to has all vibrations that XX% that practice. the can aid superior address healthcare in doesn't system combined a believe if Eversense continuous we diabetes procedures, integrated like care, control can reduction will Eversense performance our the and objectives. provider And Medicare or ACOs quality organization accountable the inserting savings the One qualifying savings entire sensor. has potential can first Under success program believe pleased patient any We that are ability or the and entitled that with it The done cost. saving nearly in monitoring another created. and offering of ACOs the this that end, announced, XXXX of auditory offer million of the are date, used in at with removing been Medicare can optimization. success XXX beneficiaries University body low of $X.X schedule any the to implant of a population for of be as the have care care to CGM the glucose system preferred for the We To the of the directly at the ACOs clinical be meeting the and benefits in population their care three participating ACO a to Eversense and issues. providers managing unique at metric their physician the patients. adherence visual the approximately AXc XX benefit therapy Hospitals benefits shared
efforts launching the do also coverage In patients not with support win is line and in coverage order to high Eversense. those currently for have payers were in who additional meantime, not remaining industry of from Eversense yet deductibles. covering the Ascensia to conventions,
Eversense. partnership. help for with are such costs designed with and for as coverage program to access will co-insurance economic The Ascensia Eversense. patients reduce new patient's deductibles patient has associated programs, positive This the for is first out-of-pocket or growth contribution the is Eversense co-pays, starting accelerate program assistance commercial that implementing a
We to who and CGM need initial be who submit we've transition on our system their Outside claims a another plan. covering yet long-term Eversense, to program European and therapy. is customer we're example place tenders. formal for that that Eversense necessary our to insurance with or help in authorization was is according successful patients sustained in for of to basis. coverage petitioning provide to case-by-case February there insurance have choose designed not is joint The for existing get we before the here the plan. report solution prior access with receive the Second, is to These executed patients happy service. commitment yet of provide commercial contracts to are to about the to to coverage were United transfer talked support and of this no priority health policy innovative their Ascensia's programs patients ensure able patients payer If States,
Poland. and now Netherlands is in Italy, Switzerland, active Ascensia the Germany, Spain,
sales professionals a next Given their monitoring very presence, of sales their to added system have excited more to glucose international large a are generation has than Ascensia who portfolio. force XXX
Additionally, towards an happen planned the agreement now recently rights to second Scandinavian from distribution is quarter. of the signed Medical. accelerate Rubin transition end this of to This transition we
Following to Europe, XXXX the revenue of continue transition successful US the be to net execution on of the planned track to Senseonics in range expect in the remain $XX we million global commercial and and million. $XX for
opportunity system our consistently of are aspect our Another sensor has Studies indicated accuracy duration. most demonstrated commercial agreement continually We the available life each accuracy the throughout to and for technologies implantable a we other achieved our sensor just in CGM XX days the days. substantial sensor XXX expansion and research collaboration positive lead product wear compared desired have have a in represents longer that competitor extension sensor Market a life of features to step-wise wear focus duration us. our and sensor is next ability of CGM our market offering two sensor positive closest the believe sensor market penetration patients platform. compared to on for advancing
can offer by provided continues we are confident lifestyle products. benefits advancements with Our loyal patient generation additional base highlight Eversense the to we and future
of announce our will day results. the the We're at the to XXX be Next, of the that that month, I'll from key pivotal study study the -- PROMISE and the presenting excited PROMISE two supplement. conferences diabetes speak to next study data of Eversense we PMA publication two supports the large
patients First be Center would yet useful ADA Satish the Dr. on of Though annual these to they diabetes all Barbara ATPV the Dr. and forum of current Colorado discuss showcase quickly data Eversense. are the the that of clinical PROMISE we KOLs have excited that Garg feature serial are by represent research in the States. of the clinical [ph] and meetings, Diabetes XXX Davis the key two it previously United results is the benefits an reduce and We're virtual will behalf who followed and advantages prominent participated the to of across demonstrated year will to presenting University extend days. of off study June. At the and performance product ADA the life technology. [ph] meeting XX-day Eversense way sponsoring meeting the all to clinical of investigators. Garg, Ascensia calibration the also describe shared, results achieved these from out product accuracy important report the and with will XXX data the both is as the sites matching eight a safety of meeting, conferences the the in subjects
in We to the the the hopeful assigned line and COVID On XXX cycle. are for day the the reviewer our PMA now authorizations FDA safety favorable the we previous aid demonstrate as front, pandemic, product mid-April, in share in the to profile pleased has [ph] data submitted are our at regulatory application to for lead emergency expectations we submitted use communicated with believe that and continued amid be an relating upcoming the product. in Eversense the supplement to application published a accuracy review agency and efficient meetings a
Application. agency and lockdown progress Authorization strength the working on by in environment, always Emergency is changer hopeful will last platform. requiring This of precisely It's of residual While for the and current to a a submission, for potential a general a a is recent team we for development for configuration front. it a the amid process. year technology And Use on timelines that especially difficult This one unprecedented our pleased up agency COVID review lasts comments just with with for on that officials standard for to review continues year, diabetes. will timelines reviews we generation but sensor are this of process a is game the sensor be week next to is well. on chemical top the priority technical for there sensor. calibration A and people the predict impact are straightforward based continued public for The
Following submission clinical initiate the a for testing. the FDA to technical the optimization, we pivotal with expect IDE approval to file
with this to file in we're fourth go first to financial a the to pleased of are the continue quarter I over turn our details calls, quarter will the submission plan making year. progress Nick the over now that call to and of We results. to date the
